Literature DB >> 21821359

Development of an egg hatch assay for the diagnosis of triclabendazole resistance in Fasciola hepatica: proof of concept.

I Fairweather1, D D McShane, L Shaw, S E Ellison, N T O'Hagan, E A York, A Trudgett, G P Brennan.   

Abstract

The aim of this study was to develop an Egg Hatch Assay (EHA) test for the detection of triclabendazole (TCBZ) resistance in Fasciola hepatica. A number of fluke isolates were used, of differing sensitivity to TCBZ. Eggs were exposed to solutions of triclabendazole sulphoxide (TCBZ.SO) for 14 days, then triggered to hatch. Egg development was divided into 6 distinct and easily identifiable stages: dead, empty, unembryonated, cell division, eye spot and hatched. The number of eggs reaching those stages was recorded. Initially, the discriminating dose (1% hatch) was determined for the Cullompton isolate, used as TCBZ-susceptible (TCBZ-S) standard. Once this concentration had been resolved, the response of different isolates to this concentration was examined. The hatch rate of the Fairhurst isolate was not significantly different from that of the Cullompton isolate, confirming its TCBZ-S status. The Patagonia isolate has not been exposed to TCBZ in the field and should be TCBZ-S: the results of the EHA supported this. The egg hatch response of the Oberon and Dutch isolates differed significantly from that of the Cullompton isolate; the former isolates are regarded as TCBZ-resistant (TCBZ-R) and the results confirmed this. Another isolate, the Leon isolate, was originally described as being TCBZ-R, but has since been shown to be TCBZ-S. There was no difference in its response to TCBZ.SO in the EHA from the Cullompton (and Fairhurst and Patagonia) isolate(s), further indicating its TCBZ-S status. The impact of TCBZ.SO treatment on the component stages of egg development was determined and revealed differences between the isolates. In conclusion, the results of the study have shown that it is possible to discriminate between TCBZ-S and TCBZ-R isolates of F. hepatica on the basis of the response of their eggs to an EHA and the test could be used to evaluate the TCBZ sensitivity of unknown field isolates.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21821359     DOI: 10.1016/j.vetpar.2011.07.023

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  11 in total

Review 1.  Inactivation of exogenous endoparasite stages by chemical disinfectants: current state and perspectives.

Authors:  Arwid Daugschies; Berit Bangoura; Matthias Lendner
Journal:  Parasitol Res       Date:  2013-02-08       Impact factor: 2.289

2.  Transcriptomic and proteomic profiling of peptidase expression in Fasciola hepatica eggs developing at host's body temperature.

Authors:  Jana Ilgová; Jiří Vorel; Pavel Roudnický; Lucie Škorpíková; Martin Horn; Martin Kašný
Journal:  Sci Rep       Date:  2022-06-20       Impact factor: 4.996

3.  Screening anthelmintic resistance to triclabendazole in Fasciola hepatica isolated from sheep by means of an egg hatch assay.

Authors:  David Robles-Pérez; José Manuel Martínez-Pérez; Francisco Antonio Rojo-Vázquez; María Martínez-Valladares
Journal:  BMC Vet Res       Date:  2015-08-28       Impact factor: 2.741

4.  Comparative ovicidal activity of Moringa oleifera leaf extracts on Fasciola gigantica eggs.

Authors:  Ahmed G Hegazi; Kadria N Abdel Megeed; Soad E Hassan; M M Abdelaziz; Nagwa I Toaleb; Eman E El Shanawany; Dina Aboelsoued
Journal:  Vet World       Date:  2018-02-19

5.  Inhibitory Activities of Ethanolic Extracts of Two Macrofungi Against Eggs and Miracidia of Fasciola Spp.

Authors:  Somtochukwu C Nwofor; Olajumoke A Morenikeji; Adeoye-Isijola O Morenike; Oyetunde T Oyeyemi
Journal:  Open Life Sci       Date:  2019-01-04       Impact factor: 0.938

6.  First report of closantel treatment failure against Fasciola hepatica in cattle.

Authors:  Adam Novobilský; Johan Höglund
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2015-08-28       Impact factor: 4.077

7.  The anti-fasciolasis properties of silver nanoparticles produced by Trichoderma harzianum and their improvement of the anti-fasciolasis drug triclabendazole.

Authors:  Youssuf A Gherbawy; Ismail M Shalaby; Mahmoud Syed Abd El-Sadek; Hesham M Elhariry; Banaja A Abdelilah
Journal:  Int J Mol Sci       Date:  2013-11-05       Impact factor: 5.923

8.  Assessment of flukicide efficacy against Fasciola hepatica in sheep in Sweden in the absence of a standardised test.

Authors:  Adam Novobilský; Natalia Amaya Solis; Moa Skarin; Johan Höglund
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2016-06-26       Impact factor: 4.077

Review 9.  Fasciola and fasciolosis in ruminants in Europe: Identifying research needs.

Authors:  N J Beesley; C Caminade; J Charlier; R J Flynn; J E Hodgkinson; A Martinez-Moreno; M Martinez-Valladares; J Perez; L Rinaldi; D J L Williams
Journal:  Transbound Emerg Dis       Date:  2017-10-06       Impact factor: 5.005

Review 10.  Drug resistance in liver flukes.

Authors:  I Fairweather; G P Brennan; R E B Hanna; M W Robinson; P J Skuce
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2020-01-10       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.